ClinicalTrials.gg

Program

briquilimab

Also written as “Briquilimab”, “Humanized anti-CD117 Monoclonal Antibody (JSP191)” and “JSP191”.

Its studies are mostly in Chronic Urticaria · Leukemia, Myeloid, Acute · Urticaria · Asthma · Immunologic Deficiency Syndromes, led by Jasper Therapeutics.

Furthest: phase 2, since Nov 2, 20167 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Jasper Therapeutics70 open or runningphase 2since Nov 2, 2016Nov 2, 2016none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2016First study: phase 2 study in Immunologic Deficiency SyndromesFirst studyNCT02963064 · 23 enrolled · United States
  2. Jun 10, 2020Phase 1 study in Anemia, Refractory, with Excess of BlastsNCT04429191 · 32 enrolled · United States
  3. Jun 5, 2023Phase 1 study in CytopeniaNCT05903274 · 6 enrolled · United States
  4. Nov 21, 2023Phase 2 study in Chronic UrticariaNCT06162728 · 87 enrolled · United States, Germany
  5. Apr 3, 2024Phase 2 study in Chronic Inducible UrticariaNCT06353971 · 27 enrolled · Germany
  6. Sep 6, 2024Phase 1 study in AsthmaNCT06592768 · 17 enrolled · Canada
  7. Nov 20, 2024Phase 2 study in Chronic UrticariaNCT06736262 · 67 enrolled · United States, Germany

TargetBeta

KIT →read by rule
“A humanized monoclonal antibody directed against CD117 (tyrosine-protein kinase KIT; c-Kit; mast/stem cell growth factor receptor; SCFR), that can potentially be used to deplete hematopoietic stem cells (HSCs)”NCIt, by rule
“Stem cell growth factor receptor inhibitor”ChEMBL 37, by rule

Other programs on KIT

ProgramCompanyFurthest phaseStudies
imatinibruleNovartisphase 470
regorafenibruleBayerphase 440
AvapritinibruleSanofiphase 410
anlotinibruleSino Biopharmaceuticalphase 340
masitinibruleAB Sciencephase 338
quizartinibruleDaiichi Sankyophase 322
ripretinibruleOno Pharmaceuticalphase 39
velzatinibGlaxoSmithKlinephase 38
seralutinibrulegb002-inc-a-wholly-owned-subsidiary-of-gossamer-bio-incphase 38
elenestinibSanofiphase 33
NB-003ruleningbo-newbay-technology-development-co-ltdphase 32
BLU-808Sanofiphase 23

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06736262Chronic Urticaria · United States, Germany2TerminatedJul 21, 202667
NCT06592768Asthma · Canada1TerminatedAug 11, 202517
NCT06353971Chronic Inducible Urticaria · Germany2TerminatedJul 31, 202527
NCT06162728Chronic Urticaria · United States, Germany2CompletedJul 8, 202687
NCT05903274Cytopenia · United States1TerminatedOct 21, 20246
NCT04429191Anemia, Refractory, with Excess of Blasts · United States1CompletedJun 13, 202332
NCT02963064Immunologic Deficiency Syndromes · United States2TerminatedJul 7, 202523

How it is read

Names in the registry

  • “Briquilimab”, 4 entries
  • “Humanized anti-CD117 Monoclonal Antibody (JSP191)”, 2 entries
  • “JSP191”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.